摘要
目的探究FLAG方案治疗难治复发性急性白血病的临床疗效。方法择取2017年3月—2018年12月期间医院收治的76例难治复发性急性白血病患者为研究对象,随机分为对照组与观察组,每组38例。对照组患者行MEA方案治疗,观察组患者行FLAG方案治疗,比较两组患者肿瘤控制效果以及不良反应发生率。结果观察组患者肿瘤控制效果73.68%高于对照组50.00%,差异有统计学意义(P<0.05);观察组患者总不良反应发生率31.58%低于对照组55.26%,差异有统计学意义(P<0.05)。结论FLAG方案治疗难治复发性急性白血病效果较为理想,同时具有较高的安全性。
Objective To investigate the clinical efficacy of FLAG regimen in the treatment of refractory relapsed acute leukemia.Methods Sixtysix patients with refractory relapsed acute leukemia admitted to our hospital from March 2017 to December 2018 were enrolled in the study.They were randomly divided into control group and observation group,with 38 cases in each group.The patients in the control group were treated with MEA.The patients in the observation group were treated with FLAG.The tumor control effect and the incidence of adverse reactions were compared between the two groups.Results The tumor control effect of the observation group was 73.68%higher than that of the control group(50.00%),the difference was statistically significant(P<0.05).The incidence of total adverse reactions was 31.58%in the observation group and 55.26%lower than the control group.The difference was statistically significant(P<0.05).Conclusion The FLAG regimen is effective in the treatment of refractory relapsed acute leukemia,and it has high safety.
作者
何兵
向传平
HE Bing;XIANG Chuanping(Department of Hematology,The First People's Hospital of Yidu Hubei,Yidu Hubei 443300,China;Department of Endocrinology,The First People's Hospital of Yidu Hubei,Yidu Hubei 443300,China)
出处
《中国继续医学教育》
2020年第4期121-123,共3页
China Continuing Medical Education
